VivoSeq
Oncology

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC V8

2

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 is an early-stage landscape with 2 programs across 1 company. The most active players are Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Duvelisib

SecuraBio

Nivolumab

Bristol-Myers Squibb

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT04652960·38 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)